Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nokia Corp (NOK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Nokia CorpTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Nokia Corp vs Recursion Pharmaceuticals Inc — how do they compare? Nokia Corp trades at $10.43 (market cap $53.00B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Nokia Corp is far larger — about 29.3× Recursion Pharmaceuticals Inc's market cap, and Nokia Corp pays a 1.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

NOKRXRX
Market Cap
$53.00B$1.81B
Sector
TechnologyHealth
52-Week High
$16.83$6.79
52-Week Low
$4.13$2.84
Enterprise Value
$50.95B$1.33B
Dividend Yield
1.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nokia Corp

Nokia (NOK) trades at $10.315, up 13.1% on the day, reflecting positive momentum. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, revenue was $19.89B in 2025 with a net income margin of 3.47%, while the P/E ratio of 68.07 suggests a premium valuation. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. News highlights focus on AI infrastructure growth driving demand.

The outlook is cautiously optimistic, supported by strong analyst buy consensus (59.61%) and AI-driven demand tailwinds. However, risks include competitive pressures in telecom, volatility in cash flows, and the high P/E ratio indicating stretched valuations. Investment appeal hinges on successful execution in AI and cloud segments offsetting traditional market challenges.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX